Radiotherapy and immunotherapy in melanoma brain metastases

Johnson, 1996, Demographics of brain metastasis, Neurosurg Clin N Am, 7, 337, 10.1016/S1042-3680(18)30365-6 Sampson, 1998, Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma, J Neurosurg, 88, 11, 10.3171/jns.1998.88.1.0011 Yu, 2002, Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery, Int J Radiat Oncol Biol Phys, 52, 1277, 10.1016/S0360-3016(01)02772-9 Ramakrishna, 2013, Multidisciplinary approach to brain metastasis from melanoma; local therapies for central nervous system metastases, Am Soc Clin Oncol Educ Book, 399, 10.14694/EdBook_AM.2013.33.399 Tawbi, 2018, Combined nivolumab and ipilimumab in melanoma metastatic to the brain, N Engl J Med, 379, 722, 10.1056/NEJMoa1805453 Long, 2018, Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study, Lancet Oncol, 19, 672, 10.1016/S1470-2045(18)30139-6 White, 2020, Melanoma brain metastases: is it time to eliminate radiotherapy?, J Neurooncol, 149, 27, 10.1007/s11060-020-03485-w Glitza Oliva, 2018, Advances in the systemic treatment of melanoma brain metastases, Ann Oncol, 29, 1509, 10.1093/annonc/mdy185 Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, 373, 1627, 10.1056/NEJMoa1507643 Margolin, 2012, Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial, Lancet Oncol, 13, 459, 10.1016/S1470-2045(12)70090-6 Gauvain, 2018, Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases, Lung Cancer, 116, 62, 10.1016/j.lungcan.2017.12.008 Goldberg, 2016, Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial, Lancet Oncol, 17, 976, 10.1016/S1470-2045(16)30053-5 Turajlic, 2018, Immunotherapy for melanoma metastatic to the brain, N Engl J Med, 379, 789, 10.1056/NEJMe1807752 Rulli, 2019, The impact of targeted therapies and immunotherapy in melanoma brain metastases: a systematic review and meta-analysis, Cancer, 125, 3776, 10.1002/cncr.32375 Cohen-Inbar, 2016, Melanoma brain metastasis pseudoprogression after pembrolizumab treatment, Cancer Immunol Res, 4, 179, 10.1158/2326-6066.CIR-15-0160 Fares, 2019, Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients?, Am Soc Clin Oncol Educ Book, 39, 147, 10.1200/EDBK_240837 Pfannenstiel, 2018, Combination PD-1 blockade and irradiation of brain metastasis induces an effective abscopal effect in melanoma, Oncoimmunology, 8 Sharabi, 2015, Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy, Lancet Oncol, 16, e498, 10.1016/S1470-2045(15)00007-8 Park, 2015, PD-1 restrains radiotherapy-induced abscopal effect, Cancer Immunol Res, 3, 610, 10.1158/2326-6066.CIR-14-0138 Reynders, 2015, The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant, Cancer Treat Rev, 41, 503, 10.1016/j.ctrv.2015.03.011 McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA 2018;319:388–96. Richardson, 1995, The well-built clinical question: a key to evidence-based decisions, ACP J Club, 123, A12, 10.7326/ACPJC-1995-123-3-A12 Sperduto, 2010, diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4259 patients, Int J Radiat Oncol Biol Phys, 77, 655, 10.1016/j.ijrobp.2009.08.025 Sperduto, 2012, Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases, J Clin Oncol, 30, 419, 10.1200/JCO.2011.38.0527 Okada, 2015, Immunotherapy response assessment in neuro-oncology: a report of the RANO working group, Lancet Oncol, 16, e534, 10.1016/S1470-2045(15)00088-1 Eisenhauer, 2009, New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 NIH. Quality Assessment Tool for Controlled Intervention Studies. National Institutes of Health Web site; 2021. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools. NIH. Quality Assessment Tool for observational Cohort and Cross-Sectional Studies. National Institutes of Health Web site; 2021. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools. Yang, 2021, Efficacy and safety of combined brain radiotherapy and immunotherapy in non-small-cell lung cancer with brain metastases: a systematic review and meta-analysis, Clin Lung Cancer, 10.1016/j.cllc.2021.06.009 Begg, 1994, Operating characteristics of a rank correlation test for publication bias, Biometrics, 50, 1088, 10.2307/2533446 Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ, 315, 629, 10.1136/bmj.315.7109.629 Acharya, 2017, Distant intracranial failure in melanoma brain metastases treated with stereotactic radiosurgery in the era of immunotherapy and targeted agents, Adv Radiat Oncol, 2, 572, 10.1016/j.adro.2017.07.003 Ahmed, 2016, Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy, Ann Oncol, 27, 434, 10.1093/annonc/mdv622 Amaral, 2019, Immunotherapy plus surgery/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis, Immunotherapy, 11, 297, 10.2217/imt-2018-0149 Amaral, 2020, Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients, J Immunother Cancer, 8, 10.1136/jitc-2019-000333 An, 2017, Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control, Radiother Oncol, 125, 80, 10.1016/j.radonc.2017.08.009 Anderson, 2017, Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment, J Immunother Cancer, 5, 76, 10.1186/s40425-017-0282-x Borzillo, 2021, Ipilimumab and stereotactic radiosurgery with CyberKnife® system in melanoma brain metastases: a retrospective monoinstitutional experience, Cancers (Basel)., 13, 1857, 10.3390/cancers13081857 Carron, 2020, Stereotactic radiosurgery combined with anti-PD1 for the management of melanoma brain metastases: a retrospective study of safety and efficacy, Eur J Cancer, 135, 52, 10.1016/j.ejca.2020.04.028 Choong, 2017, Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies, Eur J Cancer, 75, 169, 10.1016/j.ejca.2017.01.007 Krummel, 2020, Impact of sequencing radiation therapy and immune checkpoint inhibitors in the treatment of melanoma brain metastases, Int J Radiat Oncol Biol Phys, 108, 157, 10.1016/j.ijrobp.2020.01.043 Diao, 2018, Combination ipilimumab and radiosurgery for brain metastases: tumor, edema, and adverse radiation effects, J Neurosurg, 129, 1397, 10.3171/2017.7.JNS171286 Gabani, 2018, Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: patterns of care and treatment outcomes, Radiother Oncol, 128, 266, 10.1016/j.radonc.2018.06.017 Galli, 2019, Combination of immunotherapy and brain radiotherapy in metastatic melanoma: a retrospective analysis, Oncol Res Treat, 42, 182, 10.1159/000497211 Gatterbauer, 2020, Toxicity and efficacy of Gamma Knife radiosurgery for brain metastases in melanoma patients treated with immunotherapy or targeted therapy—A retrospective cohort study, Cancer Med, 9, 4026, 10.1002/cam4.3021 Gaudy-Marqueste, 2017, Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery, Eur J Cancer, 84, 44, 10.1016/j.ejca.2017.07.017 Gerber, 2015, Ipilimumab and whole-brain radiation therapy for melanoma brain metastases, J Neurooncol, 121, 159, 10.1007/s11060-014-1617-9 Kaidar-Person, 2017, The incidence of radiation necrosis following stereotactic radiotherapy for melanoma brain metastases: the potential impact of immunotherapy, Anticancer Drugs, 28, 669, 10.1097/CAD.0000000000000497 Kiess, 2015, Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment, Int J Radiat Oncol Biol Phys, 92, 368, 10.1016/j.ijrobp.2015.01.004 Knisely, 2012, Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival, J Neurosurg, 117, 227, 10.3171/2012.5.JNS111929 Liermann, 2020, Stereotactic radiosurgery with concurrent immunotherapy in melanoma brain metastases is feasible and effective, Front Oncol, 10, 10.3389/fonc.2020.592796 Mathew, 2013, Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery, Melanoma Res, 23, 191, 10.1097/CMR.0b013e32835f3d90 Minniti, 2019, Stereotactic radiosurgery combined with nivolumab or ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity, J Immunother Cancer, 7, 102, 10.1186/s40425-019-0588-y Moyers, 2021, Real-world outcomes of combination and timing of immunotherapy with radiotherapy for melanoma with brain metastases, Cancer Med, 10, 1201, 10.1002/cam4.3716 Nardin, 2018, Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases, Melanoma Res, 28, 111, 10.1097/CMR.0000000000000413 Olson, 2016, Outcomes and toxicity of stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab, Melanoma Manag, 3, 177, 10.2217/mmt-2016-0004 Parakh, 2017, Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases, Br J Cancer, 116, 1558, 10.1038/bjc.2017.142 Patel, 2017, Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases, Am J Clin Oncol, 40, 444, 10.1097/COC.0000000000000199 Tétu, 2019, Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort, Eur J Cancer, 112, 38, 10.1016/j.ejca.2019.02.009 Qian, 2016, Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery, Cancer, 122, 3051, 10.1002/cncr.30138 Rhun, 2020, Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma, ESMO Open, 5 Robin, 2018, Immune checkpoint inhibitors and radiosurgery for newly diagnosed melanoma brain metastases, J Neurooncol, 140, 55, 10.1007/s11060-018-2930-5 Schmidberger, 2018, Strahlenther Onkol, 194, 1144, 10.1007/s00066-018-1356-5 Silk, 2013, Ipilimumab and radiation therapy for melanoma brain metastases, Cancer Med, 2, 899, 10.1002/cam4.140 Skrepnik, 2017, Improved time to disease progression in the brain in patients with melanoma brain metastases treated with concurrent delivery of radiosurgery and ipilimumab, Oncoimmunology, 6, 10.1080/2162402X.2017.1283461 Stera, 2019, Stereotactic radiosurgery combined with immune checkpoint inhibitors or kinase inhibitors for patients with multiple brain metastases of malignant melanoma, Melanoma Res, 29, 187, 10.1097/CMR.0000000000000542 Stokes, 2017, Impact of immunotherapy among patients with melanoma brain metastases managed with radiotherapy, J Neuroimmunol, 313, 118, 10.1016/j.jneuroim.2017.10.006 Tazi, 2015, Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery, Cancer Med, 4, 1, 10.1002/cam4.315 Theurich, 2016, Local tumor treatment in combination with systemic ipilimumab immunotherapy prolongs overall survival in patients with advanced malignant melanoma, Cancer Immunol Res, 4, 744, 10.1158/2326-6066.CIR-15-0156 Trommer-Nestler, 2018, Robotic stereotactic radiosurgery in melanoma patients with brain metastases under simultaneous anti-PD-1 treatment, Int J Mol Sci, 19, 2653, 10.3390/ijms19092653 Williams, 2017, Phase 1 study of ipilimumab combined with whole-brain radiation therapy or radiosurgery for melanoma patients with brain metastases, Int J Radiat Oncol Biol Phys, 99, 22, 10.1016/j.ijrobp.2017.05.028 Wu, 2021, Survival Benefits of anti-PD-1 therapy in combination with radiotherapy in chinese melanoma patients with brain metastasis, Front Oncol, 11 Yusuf, 2017, Peri-SRS administration of immune checkpoint therapy for melanoma metastatic to the brain: investigating the efficacy and the effects of relative treatment timing on lesion response, World Neurosurg, 100, 10.1016/j.wneu.2017.01.101 D'Andrea, 2020, Brain radiation-induced extracranial abscopal effects in metastatic melanoma, Am J Clin Oncol, 43, 836, 10.1097/COC.0000000000000760 Hiniker, 2016, A prospective clinical trial combining radiation therapy with systemic immunotherapy in metastatic melanoma, Int J Radiat Oncol Biol Phys, 96, 578, 10.1016/j.ijrobp.2016.07.005 Patel, 2015, Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases, Neuro Oncol, 17, 1312, 10.1093/neuonc/nov093 Rauschenberg, 2019, Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases, Eur J Cancer, 110, 11, 10.1016/j.ejca.2018.12.023 Franken, 2019, A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma, Eur J Cancer, 123, 58, 10.1016/j.ejca.2019.08.032 Sperduto, 2012, Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases, J Clin Oncol, 30, 419, 10.1200/JCO.2011.38.0527 Parakh, 2019, Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma, Asia Pac J Clin Oncol, 15, 26, 10.1111/ajco.13100 Altomonte, 2013, Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme, J Exp Clin Cancer Res, 32, 82, 10.1186/1756-9966-32-82 Berrocal, 2014, Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program, Melanoma Res, 24, 577, 10.1097/CMR.0000000000000108 Chasset, 2015, Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma: negative impact of baseline corticosteroids, Eur J Dermatol, 25, 36, 10.1684/ejd.2014.2471 Gonzalez-Cao, 2017, Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program, Clin Transl Oncol, 19, 761, 10.1007/s12094-016-1602-1 Kluger, 2019, Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase ii trial, J Clin Oncol, 37, 52, 10.1200/JCO.18.00204 Konstantinou, 2014, Ipilimumab in melanoma patients with brain metastasis: a retrospective multicentre evaluation of thirty-eight patients, Acta Derm Venereol, 94, 45, 10.2340/00015555-1654 Dovedi, 2017, Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD-1 blockade, Clin Cancer Res, 23, 5514, 10.1158/1078-0432.CCR-16-1673 Roger, 2018, Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients, Oncoimmunology, 7, 10.1080/2162402X.2018.1442166 Chandra, 2015, A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab, Oncoimmunology, 4, 10.1080/2162402X.2015.1046028 Saiag, 2019, Efficacy of hypofractionated radiotherapy (RX) in melanoma patients who failed anti-PD-1 monotherapy: assessing the abscopal effect, J Clin Oncol, 37, 9537, 10.1200/JCO.2019.37.15_suppl.9537 Ngiow, 2015, Radiotherapy complements immune checkpoint blockade, Cancer Cell, 27, 437, 10.1016/j.ccell.2015.03.015 Flippot, 2019, Safety and efficacy of nivolumab in brain metastases from renal cell carcinoma: results of the GETUG-AFU 26 NIVOREN multicenter phase ii study, J Clin Oncol, 37, 2008, 10.1200/JCO.18.02218 Kohutek, 2015, Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases, J Neurooncol, 125, 149, 10.1007/s11060-015-1881-3 Crossen, 1994, neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy, J Clin Oncol, 12, 627, 10.1200/JCO.1994.12.3.627 Kim, 2021, Immune checkpoint inhibitor with or without radiotherapy in melanoma patients with brain metastases: a systematic review and meta-analysis, Korean J Radiol, 22, 584, 10.3348/kjr.2020.0728 2019, The impact of sequencing PD-1/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis., Neuro Oncol, 21, 1060, 10.1093/neuonc/noz046